Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 14/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 11/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.75 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.57 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.57 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28455573 | 0.87 | ADORA2A (0.76) | ADORA2AADORA1ADORA2BADORA3HSP90AA1 | |
| SCHEMBL1755068 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL31061536 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3HSP90AA1 | |
| SCHEMBL22359367 | 0.85 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADORA3HSP90AA1 | |
| SCHEMBL20878863 | 0.84 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADORA3HSP90AA1 | |
| SCHEMBL5731471 | 0.82 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADORA3HSP90AA1 | |
| SCHEMBL987368 | 0.82 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3HSP90AA1 | |
| SCHEMBL4742892 | 0.82 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADORA3HSP90AA1 | |
| SCHEMBL30254269 | 0.80 | ADORA2A (0.66) | ADORA2AADORA1ADORA2BADORA3HSP90AA1 | |
| SCHEMBL29157955 | 0.78 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2336133-A1 | Purine analogs having HSP90-inhibiting activity | Conforma Therapeutics Corporation (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-1962863-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | Conforma Therapeutics Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080125446-A1 | Purine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-7241890-B2 | Purine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1043021-B1 | PURINE DERIVATIVES FOR THE TREATMENT OF ALLERGIC DISEASES AND SYSTEMIC LUPUS ERYTHEMATOSUS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-0882727-B9 | NOVEL PURINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20050049263-A1 | Purine analogs having hsp90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-03-03 | — | — | US | disclosed |
| EP-1440072-A4 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | CONFORMA THERAPEUTIC CORP (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-0882727-B1 | NOVEL PURINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1440072-A2 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | Conforma Therapeutic Corporation (US) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037860-A2 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | CONFORMA THERAPEUTICS CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
| US-6376501-B1 | INHIBITING OR REGULATING IMMUNE RESPONSE USING PURINE-DERIVED COMPOUND; NON-STEROIDAL COMPOUND | JAPAN ENERGY CORPORATION (JP) | 2002-04-23 | — | — | US | disclosed |
| EP-1043021-A1 | TYPE 2 HELPER T CELL-SELECTIVE IMMUNE RESPONSE SUPPRESSORS | Japan Energy Corporation (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-6028076-A | FOR INDUCING .ALPHA.-INTERFERON IN A PATIENT HAVING HEPATITIS B OR C, BY ADMINISTERING PURINE DERIVATIVE | JAPAN ENERGY CORPORATION (JP) | 2000-02-22 | — | — | US | disclosed |
| EP-0882727-A1 | NOVEL PURINE DERIVATIVES | JAPAN ENERGY CORPORATION (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125446-A1 | Purine analogs having HSP90-inhibiting activity | HSP90B1, HSP90AB1, HSP90AA1 | ADORA2A 147/4885ADORA1 322/4885ADORA2B 485/4885 |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | ADORA2A 116/4885ADORA1 198/4885ADORA2B 340/4885 |
| US-20050049263-A1 | Purine analogs having hsp90-inhibiting activity | HSP90B1, HSP90AB1, HSP90AA1 | ADORA2A 147/4885ADORA1 322/4885ADORA2B 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.